Dolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV(combined results of the main trial and the ‘under 14kg’ cohort)

Authors: Turkova A on behalf of the ODYSSEY trial team

Presented at: CHIVA 2021